Author

Silvio Danese 1

1 Istituto Clinico Humanitas IBD Center

A TREAT TO TARGET APPROACH DECREASES THE RATE OF CD-RELATED ADVERSE OUTCOMES VERSUS A CLINICAL APPROACH IN PATIENTS WITH MODERATE TO SEVERELY ACTIVE CROHN'S DISEASE: DATA FROM CALM

Jean-Frederic Colombel, Remo Panaccione, Peter Bossuyt, Filip Baert, T. Vanásek, Ahmet Danalıoğlu, Gottfried Novacek, Alessandro Armuzzi, Xavier Hebuterne, Simon Travis, Silvio Danese, Walter Reinisch, William Sandborn, Paul Rutgeerts, Daniel W. Hommes, Stefan Schreiber, Ezequiel Neimark, Bidan Huang, Qian Zhou, Wan J Le

ANDECALIXIMAB (ANTI-MMP9) INDUCTION THERAPY FOR ULCERATIVE COLITIS: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 STUDY

William Sandborn, Bal R. Bhandari, Charles Randall, Ziad Younes, Tomasz Romańczyk, Hao Chai, Matthew McKevitt, Sally Zhao, Bittoo Kanwar, John Sundy, Satish Keshav, Silvio Danese

Anti-adhesion therapies

Silvio Danese

Assessment of Budesonide MMX® effectiveness for active, mild-to-moderate ulcerative colitis in the Polish sub-group of the prospective multi-center observational study CORE Practice

Grażyna Rydzewska, Kristine Paridaens, Silvio Danese, Maciej Jesionowski

BIOMARKER ANALYSES FROM A PHASE 2 STUDY EVALUATING THE ANTI-INTERLEUKIN-13 ANTIBODY TRALOKINUMAB IN PATIENTS WITH ULCERATIVE COLITIS

Clare Balendran, Jan Kilhamn, Stefan Pierrou, Erika Rehnström, Neil Henderson, Kevin Randall, Glen Hughes, Mikael Knutsson, Fredrik Erlandsson, Mark Hansen, Silvio Danese

BUDESONIDE MMX® EFFICACY IS INDEPENDENT OF PREVIOUS MESALAZINE EXPOSURE IN ULCERATIVE COLITIS: POOLED ANALYSIS OF CORE I AND CORE II

Silvio Danese, Limas Kupcinskas, E. David Ballard, Raul Harris-Collazo, Yun Hardiman, Michael Huang, Simon Travis

CLINICAL AND ENDOSCOPIC RESPONSE TO TREAT-TO-TARGET VERSUS STANDARD OF CARE IN CROHN'S DISEASE PATIENTS TREATED WITH USTEKINUMAB: WEEK 48 RESULTS OF THE STARDUST TRIAL

Silvio Danese, Severine Vermeire, Geert R. D'Haens, Julian Panés, Axel Dignass, Fernando Jose Magro Dias, Maciek Nazar, Manuela Le Bars, Marjolein Lahaye, Lioudmila Ni, Fréderic Lavie, Ivana Bravata, Sheldon Sloan, Marco Daperno, Milan Lukas, Alessandro Armuzzi, Mark Lowenberg, Daniel R. Gaya, Laurent Peyrin-Biroulet

CLINICAL AND ENDOSCOPIC RESPONSE TO TREAT-TO-TARGET VERSUS STANDARD OF CARE IN CROHN’S DISEASE PATIENTS TREATED WITH USTEKINUMAB: WEEK 48 RESULTS OF THE STARDUST TRIAL

Silvio Danese

CLINICALLY ADJUSTED VERSUS THERAPEUTIC DRUG MONITORING DOSING REGIMENS WITH ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM THE SERENE-CD MAINTENANCE STUDY

Silvio Danese, William Sandborn, Edward V. Loftus Jr., Stephen B Hanauer, Stefan Schreiber, Laurent Peyrin-Biroulet, Remo Panaccione, Julian Panés, Filip Baert, Jean-Frederic Colombel, Marc Ferrante, Edouard Louis, Alessandro Armuzzi, Sasikiran Goteti, John Liu, Nael M. Mostafa, Thao Doan, Joel Petersson, Anne M. Robinson

CLINICALLY ADJUSTED VERSUS THERAPEUTIC DRUG MONITORING DOSING REGIMENS WITH ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM THE SERENE-CD MAINTENANCE STUDY

Silvio Danese

Item 1 - 10 / 122
1
2 3 4 5 6 7
...
12 13